News
Empagliflozin Secures Reimbursement for Heart Failure Treatment
Starting May 1st, health insurance companies will cover Jardiance® (empagliflozin) for patients with heart failure with reduced ejection fraction. Cardiologists, pediatric cardiologists, angiologists, and internists will be able to prescribe it with reimbursement. This decision was made by the State Institute for Drug Control (SÚKL) in mid-April. Hundreds of thousands of Czechs suffering from this serious condition will now have access to another effective medication. The drug is manufactured by Boehringer Ingelheim.
Gut-Brain Axis − Future of MS Treatment?
The relationship between the gut microbiome and multiple sclerosis has been a major topic recently. How far has current science progressed in decoding this issue? A recent review article published in…
Teriflunomide under the microscope in studies and practice
Not always do the conclusions from clinical studies fully confirm in real clinical practice. Does this also apply to teriflunomide? Is its efficacy and safety consistent across age groups and…
Is it possible to extend the life of diabetics thanks to modern treatment?
People aged 60 with type 2 diabetes are estimated to live on average 6-7 years less compared to their peers without a diabetes diagnosis. However, clinical study results suggest that modern therapy…
Extract from Aloe barbadensis in the Treatment of Irritable Bowel Syndrome
The authors of a pooled analysis of two randomized controlled trials evaluated whether administration of Aloe barbadensis extract in patients with diarrhea-predominant irritable bowel syndrome (IBS)…
Updated Recommendations for Treatment of von Willebrand Disease
In 2021, new recommendations for the therapy of von Willebrand disease (vWD) were published, based on a consensus by the American Society of Hematology (ASH), the International Society on Thrombosis…
Efficacy and Safety of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction
Previous studies have shown that the antidiabetic drug empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with reduced left…
Brentuximab Vedotin in Patients with R/R cHL in the Real World: What to Expect?
How does brentuximab vedotin (BV) perform as maintenance therapy in real-world practice for patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL) who have undergone autologous…
What Response to the COVID-19 Vaccine Can Be Expected in Patients After Stem Cell Transplantation?
During the recent virtual congress of the European Society for Blood and Marrow Transplantation (EBMT 2022), a study by Saudi experts was presented that explored the response to vaccination against…
News in the Treatment of Allergic Rhinitis
According to literary sources, 17–28.5% of Europeans suffer from allergic rhinitis (AR), which negatively affects the quality of daily life. Below, we summarize the new recommendations from ARIA…
Benefits of Combining Olopatadine and Mometasone in the Treatment of Allergic Rhinitis
Ryaltris is indicated for adults and adolescents aged 12 years and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis (AR). The active ingredient of the…
Efficacy and Safety of Fixed Combination of Olopatadine and Mometasone in Nasal Spray for Treatment of Seasonal Allergic Rhinitis
Patients with allergic rhinitis require medications with rapid onset and long duration of action. The combination of intranasal antihistamines and corticosteroids has proven effective in the past.…
Luck in Unluckiness: Influence of Anticoagulant Therapy on Severity of Stroke in Atrial Fibrillation
A recent Swiss study evaluated the severity, complications, and outcomes of cerebrovascular accidents (CVAs) in patients with atrial fibrillation considering prior anticoagulant therapy use and its…
Gliflozins Successfully Treat Type 2 Diabetes Mellitus and Heart Failure
The number of patients with type 2 diabetes mellitus (DM2) and heart failure is increasing worldwide, and the combination of both diseases significantly worsens the prognosis of patients. One of the…
New Drug in the Biologic Therapy Arsenal for Plaque Psoriasis
Bimekizumab shows promising effects in clinical studies with psoriasis patients. Let's take a closer look at this recently approved drug in our brief summary.
Popular this week
- CLINICAL SPEECH THERAPIST ACCORDING TO O*NET DATABASE
- The impact of premature ejaculation treatment on a couple’s sexual function
- BENIGN DERMATOSIS OF PENIS
- Fractures of the fifth metatarsal base
- HCG level after embryo transfer as a prognostic indicator of pregnancy finished with delivery